63 episodes

Dr. Bernard Monteleone, former Head of Cardiology at St. Francis Hospital in New York, gives an informed analysis of highly-anticipated trials and whether or not their findings could impact clinical practice guidelines and reduce the risk of cardiovascular disease.

Practice Impact Extra AccessCardiology

    • Science
    • 5.0 • 1 Rating

Dr. Bernard Monteleone, former Head of Cardiology at St. Francis Hospital in New York, gives an informed analysis of highly-anticipated trials and whether or not their findings could impact clinical practice guidelines and reduce the risk of cardiovascular disease.

    64 Heart Benefits Of Coffee

    64 Heart Benefits Of Coffee

    Can coffee reduce the risk of heart failure?

    • 3 min
    63 Covid Patients And Elevated Troponin

    63 Covid Patients And Elevated Troponin

    Can CMR identify heart disease in Covid-19 patients with elevated Troponin?

    • 4 min
    62 Hypertension And Sex Differences

    62 Hypertension And Sex Differences

    Should the present guideline targets for hypertension for women be modified?

    • 4 min
    61 SCORED And Cardiovascular Events

    61 SCORED And Cardiovascular Events

    Can a new SGLT2/1 sotagliflozin reduce CV events?

    • 2 min
    60 SOLOIST And SCORED Trials

    60 SOLOIST And SCORED Trials

    Is there any additional benefit in outcomes noted for the SGLT2/1 drug Sotagliflozin in improving heart failure outcomes?

    • 3 min
    59 VITAL - RHYTHM Trial

    59 VITAL - RHYTHM Trial

    Any benefit of Omega 3 fatty acid in the prevention of atrial fibrillation?

    • 3 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science